Matthew Marx
About Matthew Marx
Matthew Marx serves as the Senior Vice President of Drug Discovery at Mirati Therapeutics, where he has worked since 2016. He specializes in structure-based and fragment-based drug discovery, with over 25 years of experience in drug discovery and medicinal chemistry.
Work at Mirati Therapeutics
Matthew Marx has served as the Senior Vice President of Drug Discovery at Mirati Therapeutics since 2016. In this role, he oversees drug discovery initiatives and strategies within the organization. His leadership has contributed to advancements in various therapeutic areas, including oncology and inflammation/immunology. He has been instrumental in managing teams and fostering collaboration to drive drug development projects forward in the Greater San Diego Area.
Education and Expertise
Matthew Marx earned both his Bachelor of Science and Ph.D. in Chemistry from the University of California, Berkeley. His academic background laid the foundation for his expertise in structure-based drug discovery (SBDD) and fragment-based drug discovery (FBDD). He possesses extensive knowledge in managing synthetic and medicinal chemistry, drug metabolism and pharmacokinetics (DMPK), protein chemistry, crystallography, and molecular modeling activities.
Background
Matthew Marx has over 25 years of post-Ph.D. experience in drug discovery and medicinal chemistry. He began his career as a Postdoctoral Fellow at The University of Texas at Austin from 1996 to 1998. He then joined Pfizer, where he worked for 12 years as an Associate Research Fellow in Oncology Chemistry. Following his tenure at Pfizer, he held the position of Department Head and Senior Director of Chemistry at Takeda Pharmaceuticals from 2010 to 2015.
Achievements in Drug Discovery
Throughout his career, Matthew Marx has demonstrated significant leadership in drug discovery strategy and collaboration management. He has managed teams of over 125 full-time employees and contractors across various therapeutic areas, including oncology, cardiovascular/metabolism, and virology. His experience also includes serving as a Scientific Advisory Board Member at IntelliSyn R&D from 2016 to 2018, where he contributed to research and development initiatives.